{"product_id":"biolegend-103133","title":"Biolegend, 103133, Brilliant Violet 421™ anti-mouse CD45 Antibody, 125microl","description":"\u003cp\u003eCD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.\u003cbr\u003e\n125microl\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse thymus or spleen\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.\u003cbr\u003e\nConcentration: µg sizes: 0.2 mg\/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested SB - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450\/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).\u003cbr\u003e\nAdditional Product Notes: Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed Naito H, et al. 2020. Nature Protocols. 15(3):1066-1081. PubMed Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed Ando M, et al. 2021. Cancer Res Commun. 1:41. PubMed Takimoto Y, et al. 2023. iScience. 26:106220. PubMed Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed Willows JW, et al. 2023. iScience. 26:106189. PubMed Chung KJ, et al. 2023. Int J Mol Sci. 24:. PubMed Cui W, et al. 2023. J Exp Med. 220:. PubMed Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed Deng G, et al. 2023. Cancers (Basel). 15:. PubMed Deng P, et al. 2022. J Clin Invest. 132: . PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Millar FR, et al. 2022. Cell Rep. 41:111596. PubMed Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed Pariury H, et al. 2023. Haematologica. :. PubMed Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Schlecht A, et al. 2021. Int J Mol Sci. 22:. PubMed Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed Ulland TK et al. 2017. Cell. 170(4):649-663 . PubMed Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed Galán-Díez M, et al. 2022. Cancer Discov. . PubMed Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed Deng J, et al. 2021. JCI Insight. 6:146133. PubMed Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed Kobayashi T, et al. 2019. Cell. 176:982. PubMed Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed Karlsson J, et al. 2021. Adv Funct Mater. 31:. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed Song WM, et al. 2018. J Exp Med. 215:745. PubMed Shmeleva EV, et al. 2019. Front Immunol. 10:1780. PubMed Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed Cui Z, et al. 2022. Bone Res. 10:58. PubMed Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed Schlecht A, et al. 2021. Front Cell Dev Biol. 8:618598. PubMed Mathur S, et al. 2021. JCI Insight. 6:. PubMed Bell BJ, et al. 2022. Brain Behav Immun Health. 23:100478. PubMed Helm M, et al. 2022. Life (Basel). 12:. PubMed Nishiga Y, et al. 2022. Nat Cancer. 3:1351. PubMed Suter EC, et al. 2021. Cell Reports. 36(8):109587. PubMed Mittal S, et al. 2016. Stem Cell Reports. 7:583-590. PubMed Saika A, et al. 2020. FASEB Bioadv. 2:59. PubMed Chu C, et al. 2016. Dis Model Mech. 9: 473-481. PubMed Hagan AS, et al. 2020. Development. 147:00:00. PubMed Kramann R, et al. 2018. JCI Insight. 3. PubMed Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed Haase C, et al. 2022. Nat Methods. 19:1622. PubMed Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed Li J, et al. 2020. Elife. 9:00. PubMed Li Q, et al. 2019. Front Cell Neurosci. 12:520. PubMed Mamedov MR, et al. 2018. Immunity. 48:350. PubMed Agalave NM, et al. 2021. Front Immunol. 12:642420. PubMed Katara GK, et al. 2020. Mol Oncol. 0.729861111. PubMed de Lucía Finkel P, et al. 2021. Sci Rep. 11:12233. PubMed Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed Boeck M, et al. 2020. Glia. 1859:68. PubMed Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed Bersini S, et al. 2020. Life Sci Alliance. 3:e201900623. PubMed Durré T, et al. 2018. Nat Commun. 9:5178. PubMed Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed Ma Z, et al. 2022. Methods Mol Biol. 2471:49. PubMed Hirata SI, et al. 2020. Allergy. 75:1939. PubMed Goh W, et al. 2020. Cell Rep. 33:108285. PubMed Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed Zwick M, et al. 2019. Front Immunol. 10:222. PubMed Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed Zhang P, et al. 2021. J Neuroinflammation. 18:215. PubMed Yi H, et al. 2021. Front Immunol. 12:719189. PubMed Wieghofer P, et al. 2021. EMBO J. 40:e105123. PubMed Shibuya M, et al. 2021. iScience. 24:103131. PubMed Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed Wakabayashi T et al. 2018. Cell stem cell. 22(3):384-397 . PubMed Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed Meng Michelle Xu et al. 2017. Immunity. 47(2):363-373 . PubMed Süß P, et al. 2020. Cell Reports. 30(12):4082-4095. PubMed Ombrato L, et al. 2021. Nat Protoc. 16:872. PubMed Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed Hu B, et al. 2020. J Clin Invest. 130:3483. PubMed Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed Nishimura T, et al. 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed Usui-Ouchi A, et al. 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed Boddupalli CS, et al. 2022. Elife. 11:. PubMed Palma A, et al. 2022. Front Cell Dev Biol. 10:841548. PubMed Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed\u003cbr\u003e\nRRID: AB_10899570 (BioLegend Cat. No. 103133) AB_2562559 (BioLegend Cat. No. 103134)\u003cbr\u003e\nStructure: Protein tyrosine phosphatase (PTP) family, 180-240 kD\u003cbr\u003e\nDistribution: All hematopoietic cells except mature erythrocytes and platelets\u003cbr\u003e\nFunction: Phosphatase, T and B cell activation\u003cbr\u003e\nLigand\/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1\u003cbr\u003e\nCell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.\u003cbr\u003e\nGene ID: 19264\u003cbr\u003e\nUniProt: View information about CD45 on UniProt.org\u003cbr\u003e\nClone: 30-F11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T200, Ly-5, LCA\u003cbr\u003e\nIsotype: Rat IgG2b, κ\u003cbr\u003e\nQ: What is the F\/P ratio range of our BV421™ format antibody reagents?\u003cbr\u003e\nA: It is lot-specific. On average it ranges between 2-4.\u003cbr\u003e\nQ: If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?\u003cbr\u003e\nA: It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.\u003cbr\u003e\nQ: Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?\u003cbr\u003e\nA: Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF\/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.\u003cbr\u003e\nQ: Are other fluorophores compatible with IBEX?\u003cbr\u003e\nA: Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.\u003cbr\u003e\nQ: The same antibody works in one tissue type but not another. What is happening?\u003cbr\u003e\nA: Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.\u003cbr\u003e\nQ: How can I be sure the staining I’m seeing in my tissue is real?\u003cbr\u003e\nA: In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862363787433,"sku":"103133","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-103133","provider":"Iright","version":"1.0","type":"link"}